Business Context and Reporting Period
This Form 8-K Current Report was filed by Cocrystal Pharma, Inc. on September 22, 2020. The report addresses a legal settlement regarding a previously disclosed shareholder derivative action.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed relates to legal costs:
- Attorneys' Fees and Expenses: $275,000 to be paid by certain defendants (excluding the Company) to the plaintiffs.
Material Changes
There are no material changes to financial operations reported. The material event is the preliminary court approval of a settlement agreement dated August 20, 2020, involving the Company as a nominal defendant and certain current and former directors and officers.
Outlook, Risks, and Unusual Items
Settlement Terms:
- The settlement is subject to final approval by the United States District Court for the District of New Jersey.
- The Company is required to adopt specific corporate governance enhancements within 60 days of final court approval.
- The Company is not required to pay the $275,000 in attorneys' fees; this obligation falls on the individual defendants.
Risks and Contingencies: The primary contingency is the final court approval of the Stipulation and Agreement of Settlement. Until final approval, the terms are not binding.
Investor Verification Checklist
- Verify the final court approval status of the shareholder derivative action settlement.
- Review Exhibit A to the Stipulation (filed as Exhibit 99.2) to understand the specific corporate governance enhancements the Company must implement.
- Confirm that the Company is not liable for the $275,000 legal fee payment.
- Monitor future filings for the implementation of the required governance changes within the 60-day post-approval window.